Skip to main content

Market Overview

FDA Updates Fact Sheets For Eli Lilly, Regeneron's COVID-19 Antibody Therapies Under Emergency Use


The FDA updated its fact sheets on the monoclonal antibody (mAb) treatments for COVID-19 from Eli Lilly And Co (NYSE: LLY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN), highlighting additional data on the vulnerability of the emerging COVID-19 variants to each of the mAb therapies.

  • “Some variants can cause resistance to one or more of the mAb therapies authorized to treat COVID-19,” FDA said. “Health care providers should review the authorized fact sheets for information on the use of the authorized mAb therapies against currently circulating viral variants.”
  • The U.S. government stopped the distribution of Lilly’s bamlanivimab, in California, Nevada, and Arizona because of the variant originating in California.
  • As per FDA’s revised fact sheet for bamlanivimab, a substantial reduction in responsiveness to mAb therapies was observed for all the variants studied, except for the one originating in the U.K.
  • Updated fact sheet showed that Lilly’s combination therapy of bamlanivimab and etesevimab was better against all variants than bamlanivimab alone.
  • Updated fact sheet for Regeneron’s cocktail therapy combining casirivimab and imdevimab showed a minimum reduction in susceptibility against the variants.
  • Price Action: LLY shares were up 0.3% at $184.50, and REGN shares were trading 0.98% higher at $479.3 in market trading hours on the last check Friday.

Related Articles (REGN + LLY)

View Comments and Join the Discussion!

Posted-In: Covid-19 Emergency Use AuthorizationBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at